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PURPOSE. Hyaluronan (HA) overproduction by orbital fibroblasts (OFs) is a major factor
in the pathogenesis of Graves’ orbitopathy (GO). 4-methylumbelliferone (4-MU) is an
inhibitor of HA synthesis in different cell types in vitro and has beneficial effects in
animal models of autoimmune diseases.
METHODS.HA production and mRNA expression of HA synthases (HAS1,HAS2, andHAS3)
and hyaluronidases (HYAL1 and HYAL2) were measured in the presence and absence of
4-MU in unstimulated and transforming growth factor–β–stimulated fibroblasts from GO
orbital (n = 4), non-GO orbital (n = 4), and dermal origin (n = 4).
RESULTS. The 4-MU treatment (1 mM) for 24 hours resulted in an average 87% reduc-
tion (P < 0.001) of HA synthesis, decreased the expression of the dominant HAS isoform
(HAS2) by 80% (P < 0.0001), and increased the HYAL2 expression by 2.5-fold (P < 0.001)
in control OFs, GO OFs, and dermal fibroblasts (DFs) regardless of the origin of the cells.
The proliferation rate of all studied cell lines was reduced to an average 16% by 4-MU
(P < 0.0001) without any effects on cell viability. HA production stimulated by transform-
ing growth factor–β was decreased by 4-MU via inhibition of stimulated HAS1 expression
in addition to the observed effects of 4-MU in unstimulated cases. Characteristics of HA
synthesis inhibition by 4-MU did not differ in OFs compared with DFs.
CONCLUSIONS. 4-MU has been found to inhibit the HA synthesis and the proliferation rate
in OFs in vitro, adding it to the list of putative therapeutic agents in a disease the cure
of which is largely unresolved.
Keywords: Graves’ orbitopathy, hyaluronan, 4-methylumbelliferone, hyaluronan synthase,
hyaluronidase
Graves’ orbitopathy (GO) is an autoimmune diseaseof the orbits that may accompany Graves’ disease.1
Immune cell infiltration of the orbital tissue and local
cytokine release result in increased production of extracellu-
lar matrix glycosaminoglycans, mainly hyaluronan (HA) by
orbital fibroblasts (OFs), and extracellular matrix remodel-
ing.2,3 HA, because of its highly hydrophilic nature,4 binds
a large amount of water; edematic swelling of orbital tissues
is a known factor in the pathogenesis of GO. The obvious
incongruence between the limited volume of the bony orbit
and the expanded orbital content results in the protrusion of
the eye. HA is not a passive matrix component; it regulates
cell-cell and cell-matrix adhesion, facilitates cell-cell signal-
ing, influences the migration of immune cells, and improves
proliferation.5–8
HA is a linear polymer of repeating units of glucuronic
acid (GlcUA) and N-acetyl-glucosamine synthesized by 3
different HA synthase enzymes (HAS1, HAS2, and HAS3).9
HA synthesis is regulated by various growth factors
including transforming growth factor–β (TGF-β), which
has been found in the orbital tissue of patients with GO
and correlated positively with the clinical activity of the
disease.10 We recently demonstrated that TGF-β enhances
HA synthesis of OFs via stimulating HAS1 expression.11
The breakdown of HA is carried out by 2 isoforms of
hyaluronidases, HYAL1 and HYAL2.12
4-methylumbelliferone (4-MU) is a coumarin deriva-
tive with no anticoagulant property and is available as
a spasmolytic over-the-counter drug in several European
countries. It is a specific inhibitor of the HA synthesis
in multiple cell lines, including fibroblasts, keratinocytes,
melanoma, and pancreatic cancer cells.7,13–16 4-MU is a
substrate for uridine 5′-diphospho-glucuronyltransferases
(UDP-glucuronyltransferases), and the glucuronidation of
4-MU to form 4-methylumbelliferyl glucuronide (4-MUG)
depletes UDP-GlcUA, one of the substrates of HAS enzymes
thus limits HA synthesis.17 In addition, 4-MU decreases the
mRNA expression of HAS enzymes.18
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The 4-MU treatment was beneficial in animal models of
autoimmune diseases,16,19,20 but its potential role as a ther-
apeutic agent in GO has not been raised before.
Here we show that 4-MU is an effective inhibitor of HA
synthesis in OF in vitro both in unstimulated and TGF-
β–stimulated cells; changes of the mRNA levels of the 3
isoforms of HAS enzymes and the 2 isoforms of HYAL
enzymes, as well as proliferation rate of the cells after 4-MU
treatment have also been studied.
MATERIALS AND METHODS
Materials
M199 with Earles’ salts without L-Glumatine, peni-
cillin/streptomycin, Glutamine Stable were purchased from
Biosera (Nuaille, France), Dulbecco’s phosphate-buffered
saline solution without calcium and magnesium, trypsin–
EDTA solution, freezing medium, TrypLE Express, fetal
bovine serum (FBS) and TGF-β were purchased from
Thermo Fisher Scientific (Waltham, MA, USA). 4-MU and 4-
MUG were purchased from Sigma Aldrich (St. Louis, MO,
USA). TRI reagent solution was purchased from Molecular
Research Center, Inc. (Cincinnati, OH, USA).
Tissue Samples
Orbital connective tissues were obtained from patients
undergoing orbital decompression surgery for GO. Control
normal orbital tissues were obtained during surgery for
nonorbital eye diseases. Control dermal connective tissues
were obtained during abdominal hernia operations from
patients with no history of thyroid diseases. The character-
istics of patients are shown in the Table.
The study was approved by the Regional and Institu-
tional Ethics Committee of the University of Debrecen. The
study was carried out in accordance with the Declaration of
Helsinki. Consent has been obtained from each patient after
full explanation of the purpose and nature of all procedures
used.
Cell Cultures
Human fibroblasts were cultured as described previously in
detail.11 The cells were studied between passages 2 and 8.
For experiments, orbital and dermal fibroblasts (OFs and
DFs) were plated in 24-well or 96-well plates, in conflu-
ent cell density (1.56 × 104 cells/cm2) in M199 supple-
mented with 10% (v/v) FBS. The cultures were synchronized
with serum starvation for 24 hours followed by treatment
with medium containing 10% (v/v) FBS with or without
4-MU (0.125–6 mM) and TGF-β (1 ng/mL) or 4-MUG
(1 mM) for an additional 24 hours. The 4-MU and
4-MUG stock solutions were dissolved in dimethyl sulfox-
ide (500 mM). The final concentration of dimethyl sulfoxide
in the medium was adjusted to 0.2% in all experiments. All
experiments were performed at least 3 times and carried
out in triplicate. Secreted HA levels in cell culture super-
natants and levels of pericellular HA11 were measured using
the DuoSet Hyaluronan Kit (R&D Systems, Minneapolis,
MN, USA). In each case, results were adjusted for the HA
content of FBS. In all experiments, the HA productions were
expressed as ng/105 cells.
The effect of 4-MU on proliferation,metabolic activity and
viability were measured using Cell Proliferation ELISA BrdU
Colorimetric Kit (F. Hoffmann-La Roche Ltd, Basel, Switzer-
land), EZ4U Assay (Biomedica Medizinproducte GmbH &
Co KG, Vienna Austria) and Vybrant Cytotoxicity Assay Kit
(Thermo Fisher Scientific), respectively. The detection of
caspase-3 and -7 activities was performed using the Caspase-
Glo 3/7 Assay System (Promega Corporation, Madison, WI,
USA).
Real-Time Polymerase Chain Reactions (RT-PCR)
The supernatants were removed and cells were washed with
Dulbecco’s phosphate-buffered saline solution. TRI Reagent
Solution was used for the isolation of RNA from cells. The
purified RNA samples were reverse transcribed by High
Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Thermo Fisher Scientific, Waltham). The TaqMan
Gene Expression Assay (Applied Biosystems, Thermo Fisher
Scientific,Waltham) was used for the detection of the expres-
sion of HAS1, HAS2, HAS3, HYAL1 and HYAL2; glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was used
as housekeeping gene. The reactions were performed by
the Real-time PCR System (BioRad, Hercules, CA, USA).
Results were normalized to GAPDHmRNA levels by the CT
method.
Statistical Analysis
Statistical analysis was performed using the STATISTICA 13
software (StatSoft Inc. Tulsa, OK, USA). Data are expressed
as mean ± SD. Repeated measures analysis of variance
(ANOVA) with treatment as the within-subjects factor and
origin of fibroblasts (normal orbital fibroblasts, Graves’
orbitopathy fibroblasts and dermal fibroblasts) as between-
subjects factor and Fisher LSD post hoc analysis were
performed to evaluate the differences. The level of statistical
significance was set at P < 0.05.
RESULTS
The used 12 cell lines represented 3 different types of cells:
control OFs (n = 4), GO OFs (n = 4), and DFs (n = 4);
the amount of HA produced by these cells under normal
conditions was 675 ± 262, 479 ± 217, and 693 ± 262
ng hyaluronan/105 cells/24 hours, respectively (Fig. 1, dark
columns). The origin of fibroblasts was not a significant
factor in the HA production (control OFs vs. GO OFs: P =
0.138, control OFs vs. DFs: P = 0.884, GO OFs vs. DFs: P =
0.091).
HA production of the fibroblasts has been measured
in the supernatants after 24-hour 4-MU treatment. The HA
secreted by individual cells decreased after 4-MU treatment
in a dose-dependent manner. Dose-response experiments
were performed in the range of 0.125–6.0 mM in OFs. In the
examined range, maximum effect has been reached at 1 mM
4-MU (Fig. 2); this concentration was used in all experiments
concerning HA production and gene expressions. A strong
inhibitory effect was observed in HA production when OFs
and DFs were treated with 1 mM 4-MU (Fig. 1, gray columns).
The inhibition was 85.3% ± 2.9% in control OFs (P < 0.001),
85.4% ± 2.8% in GO OFs (P < 0.005), and 91.3% ± 1.2% in
DFs (P < 0.001); the 1 mM 4-MU treatment caused an aver-
age 86.7% decrease in HA production. The effectiveness of
4-MU did not depend on the origin of the fibroblasts (P =
0.352).
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FIGURE 1. Effect of 4-MU treatment (1 mM) on hyaluronan produc-
tion of control OFs, GO OFs, and DFs. Hyaluronan concentration in
the supernatant was expressed in ng/105 cells. Data were analyzed
using repeated measures ANOVA followed by Fisher LSD post hoc
test, results are shown as mean ± SD from five independent exper-
iments. ** P < 0.005, *** P < 0.001.
FIGURE 2. Dose-dependent influence of 4-MU treatment (0.125–
6.0 mM) on hyaluronan production of OFs. Hyaluronan concentra-
tion in the supernatant was expressed in ng/105 cells. Data were
analyzed using repeated measures ANOVA followed by Fisher LSD
post hoc test, results are shown as mean ± SD. * P < 0.01, ** P <
0.005.
There was a similar change in the amount of pericellular
HA after 24 hours’ 4-MU treatment (P < 0.05) in both control
and GO OFs, whereas a less marked effect was seen in DFs.
The inhibition was 57% ± 38% in control OFs, 58% ± 31%
in GO OFs, and 29% ± 7% in DFs.
To check whether 4-MUG, the main metabolite of 4-MU,
has an effect on HA synthesis, 4-MUG was added to the
FIGURE 3. Influence of 4-MU treatment (1 mM) on HAS2 and HAS3
mRNA expression levels in control OFs, GO OFs, and DFs. Results
adjusted for the expression of GAPDH. Data were analyzed using
repeated measures ANOVA followed by the Fisher LSD post hoc test.
Results are shown as fold change of untreated (mean ± SD) from 3
independent experiments. # P < 0.05, *** P < 0.001.
cell culture under the same conditions (1 mM for 24 hours).
4-MUG did not affect HA production (data not shown).
Next, we studied the effect of 4-MU on mRNA expression
of HAS1, HAS2, HAS3, HYAL1, and HYAL2. HAS1 expression
was too low in most of the studied cell lines to accurately
measure its basal expression. The 4-MU treatment resulted
in a significant decrease in HAS2 expression (P < 0.001)
in all cell lines (Fig. 3), and there was no difference in
the effect according to the site of origin (P = 0.268). The
reductions in HAS2 expression were 72% ± 12%, 76% ±
18% and 91% ± 3% for control OFs, GO OFs, and DFs,
respectively. In the case of HAS3 (Fig. 3) 4-MU treatment
caused a significant increase in the expression in fibrob-
lasts (P = 0.030) irrespective of the site of origin (P =
0.163). The increase was 136% ± 42% in control OFs, 199%
± 93% in GO OFs and 134% ± 35% in DFs compared with
baseline.
When hyaluronidases were studied, 4-MU treatment
decreased HYAL1 expression (P = 0.017), and the effect was
dependent on the site of origin (P = 0.042) (Fig. 4). The
post hoc analysis showed that the 4-MU treatment decreased
HYAL1 only in control OFs, by 45% ± 13% (P < 0.005). The
4-MU treatment caused a significant increase in the HYAL2
expression (P < 0.0001) (Fig. 4), and this effect was not
dependent on the origin of fibroblasts (P = 0.368). The
increase was 257% ± 72% in control OFs, 260% ± 24% in
GO OFs, and 235% ± 24% in DFs compared with baseline.
Fibroblast proliferation is an important factor in the
autoimmune process of GO. The proliferation potential of
cultures was estimated by BrdU assay. The proliferation rate
was decreased by 84% ± 4% in control OFs, 80% ± 3% in
GO OFs and 90% ± 2% in DFs incubated with 1 mM 4-MU
for 24 hours compared with cultures incubated in medium
alone (P < 0.001). As shown in Figure 5A, the effect of 4-
MU on the proliferation rate was dose dependent in the
range of 0.25–1 mM. Both the baseline proliferation rate and
the response to 4-MU were independent of the anatomical
origin of fibroblasts (P = 0.387 and P = 0.259, respectively).
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FIGURE 4. Influence of 4-MU treatment (1 mM) on HYAL1 and
HYAL2 mRNA expression levels in control OFs, GO OFs, and DFs.
Results were adjusted for the expression of GAPDH. Data were
analyzed using repeated measures ANOVA followed by the Fisher
LSD post hoc test, results are shown as fold change of untreated
(mean ± SD) from 3 independent experiments. ** P < 0.005.
To show that reduced cell proliferation is not the conse-
quence of direct toxicity of 4-MU, we used a tetrazolium salt
based assay first. The conversion of tetrazolium to formazan
by the cells was decreased after 1 mM 4-MU treatment
(P < 0.0001) by 29% ± 18% in control OFs, 34% ± 11% in
GO OFs, and 30% ± 10% in DFs; the effect of 4-MU was not
different in the fibroblasts with distinct type of origin (P =
0.356). It is known that over/underestimation of cell viability
by tetrazolium salt–based assays could happen in the case of
certain agents with modulating effects on metabolism.21 To
avoid this bias, we completed the study with a nonmetabolic
cytotoxicity assay based on measuring G6PD release from
damaged/dying cells to determine the cytotoxicity of 4-MU.
The ratio of damaged or dead cells in the 4-MU-treated
cultures did not differ from that observed in the cultures
without 4-MU in any of the studied cell lines (Fig. 5B).
Although cell viability was found unchanged within 24 hours
of 4-MU treatment, potential pro-apoptotic activity of 4-MU
was tested performing caspase-3 and -7 activity measure-
ment. No enhancing effect of 4-MU on executioner caspases
was found within 24 hours (Fig. 5C).
In a recent study we found that TGF-β increased the HA
synthesis of OFs and DFs through stimulating the expres-
sion of HAS1.11 Now we studied the effect of 4-MU on the
HA synthesis of TGF-β-stimulated cells. The 4-MU decreased
HA production added simultaneously with TGF-β (1 ng/mL)
in every studied cell line where TGF-β alone (1 ng/mL) stim-
ulated the HA synthesis (untreated vs. TGF-β treated: P =
0.036, TGF-β treated vs. TGF-β + 4-MU treated: P < 0.0001,
untreated vs. TGF-β + 4-MU treated: P < 0.005) (Fig. 6A).
There was no difference between fibroblasts with different
type of origin in this respect (P = 0.242). TGF-β also stim-
ulated HAS1 expression (P < 0.01); the stimulatory effect
was decreased by 4-MU (P = 0.034) (Fig. 6B). The expres-
sion of HAS2, HAS3, HYAL1 and HYAL2 of untreated or
4-MU treated cells did not change significantly by TGF-β
treatment.
FIGURE 5. The effect of 4-MU treatment (0.25, 0.5 and 1 mM) on
proliferation rate (A), viability (B), and caspase-3 and -7 activity
(C) of control OFs, GO OFs, and DFs. Data were analyzed using
repeated measures ANOVA followed by the Fisher LSD post hoc
test, results are shown as fold change of untreated (mean ± SD)
from 3 independent experiments. ** P < 0.005, *** P < 0.001,
**** P < 0.0001.
No associations were observed between any patient char-
acteristics and hyaluronan production of the respective
fibroblast line examined either in basic or in stimulated
conditions.
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FIGURE 6. The effect of 4-MU treatment (1 mM) on TGF-β stim-
ulated (1 ng/L) HA production (A) and HAS1 expression (B) in
the studied fibroblast lines. Data were analyzed using repeated
measures ANOVA followed by Fisher LSD post hoc test, results are
shown as mean ± SD from 3 independent experiments. # P < 0.05,
* P < 0.01, ** P < 0.005, **** P < 0.0001.
DISCUSSION
HA is a major factor in the pathogenesis of GO1; in addi-
tion to the overproduction of HA by fibroblasts, HA may
potentially retain extracellular fluid about 1000 times of its
own weight,22 leading to edema, increased orbital pressure,
and proptosis. In addition, HA may have a crucial role in
the chronic autoimmune inflammation affecting retrobulbar
connective tissue and external eye muscles. Any therapeu-
tic measure diminishing local HA production can potentially
reduce intraorbital pressure and could interfere with the
pathogenesis of GO. 4-MU has successfully been used in
animal models of autoimmunity where HA is supposed to
contribute to disease pathogenesis.16,19,20 Our in vitro study
on the characteristics of HA synthesis inhibition by 4-MU in
OFs may serve as a starting point for further research on the
potential beneficial effects of limiting HA production in GO.
In line with earlier studies on other cell types,13–16,23,24
we have found that 4-MU in the same concentration range
has inhibited HA synthesis in normal and GO OFs, as well as
DFs examined, even in the presence of TGF-β. HA produc-
tion of the OFs originated either from GO or non-GO control
orbits decreased in the same extent as it was observed in
the fibroblasts with dermal origin. This inhibition during
24-hour 4-MU treatment is mainly due to the well-known
mechanism that 4-MU depletes the cellular pool of the HA
synthesis precursor, UDP-GlcUA.17 Because it is known that
4-MU treatment reduces the expression of HAS enzymes,18
we measured the effect of 4-MU on the transcriptional levels
of several enzymes involved in HA metabolism. We found
here that 4-MU greatly reduced HAS2 mRNA expression,
whereas it increased mildly the HAS3 expression in OFs and
DFs. The same effect on HAS2 expression was described
in cancer cells in which the level of HAS3 mRNA was also
reduced except for 1 cell line with very low HAS3 expres-
sion level.18 We assume that the effect of 4-MU on tran-
scription of HAS genes with very low expression levels is
less consistent; HAS2 expression was 2 orders of magni-
tude higher than HAS1 and HAS3 in the studied cells, as
we described earlier.11 This theory is supported by our
observation that significant downregulating effect of 4-MU
on the expression of HAS1 was observed in TGF-β stimu-
lated cells where HAS1 transcription is substantially higher
(Fig. 6B). The direct effect of 4-MU on the expression of HAS
genes is still unclear, but it was described earlier that HAS1
and HAS2 expressions positively correlated with the cellular
level of both UDP-GlcUA and UDP–N-acetyl-glucosamine,25
suggesting a strong indirect effect of 4-MU due to the
UDP-GlcUA depletion. No correlation was found between
HAS3 expression and intracellular UDP-sugar contents25
suggesting that the effect of 4-MU on HAS3 expression
is less predictable. The contribution of the 4-MU induced
changes in the expression pattern of HAS enzymes to the
reduced HA production is uncertain given the fact that UDP-
GlcUA starvation prevented the localization of the intact
HAS on the plasma membrane,26 where HA synthesis can
occur.
Besides the HAS enzymes, 4-MU affected the expression
of hyaluronidases. HYAL2 is anchored to the cell surface
and generates intermediate-size HA fragments only from
the high molecular weight HA (HMW-HA), whereas HYAL1
is active in the lysosome and degrades any size of HA
as substrate generating very small HA fragments.5,12,27 Our
finding of an increased HYAL2 expression in response to
4-MU may mean acceleration of HA turnover which may
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have a beneficial effect for the disease process in GO. The
reduction of HYAL1 expression observed only in control OFs
is unlikely to influence HA metabolism to a great extent in
these cells; additional enzymes participate in the lysosomal
HA degradation.5 We assume that the main effect through
which 4-MU influences HA production in addition to its role
as a competitor for UDP-GlcUA is its reducing effect onHAS2
expression.
In previous studies on OFs the decline of HA production
was coupled with the reduction of cell proliferation.28,29 The
decreased HA synthesis by 4-MU treatment was found to be
associated with a strong reduction of proliferation rate in
keratinocytes and aortic smooth muscle cells,13,24 which has
now been confirmed in our study in OFs and DFs. Inhibi-
tion of HA synthesis leads to cell cycle arrest at mitosis, just
before cell rounding and detachment.30 A same effect of HA
synthesis inhibition by 4-MU was demonstrated in osteosar-
coma cells.31 In tumor cells 4-MU has been reported to
interfere with proliferation, motility and invasion by inhibit-
ing HA signaling events, including survival-related pathways
such as the PI3K/Akt pathway by suppressing phosphory-
lation of Akt.31–34 In the aforementioned studies downregu-
lation of the anti-apoptotic PI3K/Akt pathway by 4-MU was
accompanied by induction of apoptosis.31–33 We did not find
apoptotic effect of 4-MU in OFs and DFs within 24 hours
of treatment by performing caspase-3 and -7 activity assay;
further studies are needed to clarify this issue during longer
treatment.
4-MU has not been found cytotoxic in the concentra-
tion required for maximal inhibitory effect on HA synthe-
sis. Based on our results with several different cytotoxic-
ity assays, we assume that the formazan-based metabolic
assay could overestimate the effect of 4-MU on cell
viability.
Because the tissue microenvironment, including its HA
content contributes to the characteristics of local inflamma-
tory processes,35 4-MU in GO may have several beneficial
effects in the initiation and the course of the disease. The
4-MU treatment interfered with cell-cell interaction required
for antigen presentation36 and inhibited T-cell prolifera-
tion.37 4-MU has been found to be beneficial in animal
models of autoimmune diseases associated with increased
regulatory T-cell numbers, which play a critical role in the
protection from autoimmunity and fibrotic conditions.19,20 In
addition to limiting HA synthesis and fibroblast proliferation,
another potential positive impact of 4-MU may be its modu-
lating effect on adipogenesis of OFs, which is an important
step leading to proptosis in the pathomechanism of GO.38
Adipogenesis in OFs was accompanied by HA accumulation
and increased HAS2 expression.39 4-MU has been described
as an inhibitor of adipogenic differentiation in 3T3-L1 fibrob-
lasts40 and reduced fat pad weight and adipocyte size in
vivo.41
However, some questions arise about the use of 4-MU
as a medication. It is unclear whether, and to what extent
the effect of 4-MU is modulated by the concomitant admin-
istration of other drugs that are metabolized via the UDP-
glucuronyltransferases–mediated pathway. Another doubt is
the low bioavailability and short half-life of 4-MU; in a recent
study its main metabolite 4-MUG was found to contribute to
the bioactivity of 4-MU both in vitro and in vivo via conver-
sion to 4-MU.42 This conversion was observed in cell cultures
after 48–72 hours42; this may explain why the 24-hour
4-MUG treatment in our study was not sufficient to exert
any effect on OFs and DFs.
One potential limitation of our study is its in vitro nature.
It is not clear to what extent our findings can be translated
to the human orbit, where a more complex local environ-
ment, interaction of immune, endocrine and local factors,
including increased tissue pressure, contribute to disease
pathogenesis. Nevertheless, any of these factors are potential
targets for intervention.
We have shown here that 4-MU interferes with fibroblast
activity in at least 2 different ways, by diminishing prolifer-
ation and inhibiting HA synthesis. Further studies in animal
models of GO and a clinical trial could provide further infor-
mation on the feasibility of 4-MU as a therapeutic agent in
this disease.
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